Dechra strengthens its position in advanced veterinary therapeutics
Dechra Pharmaceuticals has entered into an agreement to acquire US-based veterinary biotechnology company Gallant Pet, strengthening its strategic interest in regenerative medicine and advanced therapeutic solutions for companion animals. The financial terms have not been disclosed. Completion remains subject to customary closing conditions.
What does Gallant Pet bring to Dechra?
Gallant is developing off-the-shelf mesenchymal stromal cell therapies for pets. Mesenchymal stromal cells are multipotent cells studied for their immunomodulatory, anti-inflammatory and tissue-repair properties.
Unlike conventional small-molecule veterinary drugs, cell-based therapies are designed to interact with biological processes in a more complex manner. Gallant’s capabilities include:
-
Veterinary cell-therapy research and development
-
Manufacturing of cell-based products
-
GMP-compliant production infrastructure
-
Development of off-the-shelf therapeutic candidates
-
Expertise in veterinary regenerative medicine
The company was founded in 2018 and operates a manufacturing facility in San Diego, California.
Why regenerative medicine matters in veterinary healthcare
Companion animals are increasingly living longer, creating demand for treatments that address chronic and degenerative conditions. Regenerative medicine is being investigated in areas including:
Osteoarthritis and joint disease – Cell-based interventions are being studied for their potential to influence inflammatory pathways and support joint function.
Immune-mediated disorders – The immunomodulatory properties of mesenchymal stromal cells have attracted interest in selected inflammatory and immune-mediated conditions.
Tissue repair – Research continues into the potential use of cell-based therapies in tissue injury and repair. However, efficacy, safety and regulatory status must be evaluated separately for each indication and product.
Strategic significance for Dechra
Dechra has traditionally built its business around differentiated veterinary medicines, particularly in specialist companion-animal and livestock segments.
Gallant provides an opportunity to expand beyond conventional pharmaceutical formulations. The acquisition could strengthen Dechra’s capabilities in:
-
Advanced biologics.
-
Veterinary specialist medicine.
-
Regenerative therapeutic development.
-
Proprietary manufacturing.
-
High-value companion-animal healthcare.


